Of note, hENT-1 is not the only potential mechanism mediating the favorable effect of NUC-1031, since this drug does not require the phosphorylation to difluorodeoxycytidine monophosphate (dFdCMP) by dCK and it preserves higher concentrations of the active triphosphate metabolite (dFdCTP) than gemcitabine at equimolar doses inside the tumor cells [6,105]. The gene discussed is SLC29A1; the disease is neoplasm.